A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy.
Sodium phenylbutyrate (NaPB) represent a new non-toxic class of compounds with antiproliferative activities to different tumors and has been shown to modulate many gene expressions by inhibiting histone deacetylation and DNA methylation as the major mechanism. Butyrate and other protein kinase C (PKC) activators have been reported to be able to activate virus enzymes. The present work investigates whether NaPB has an antiproliferative effect or modulatory effects on EBV-associated nasopharyngeal carcinoma (NPC) and whether EBV thymidine kinase gene can be activated to make cells susceptible to ganciclovir (GCV) therapy. NaPB treatment displayed a dose- and time-dependent antiproliferative effect on the NPC cell line CNE2. Cell cycle analysis revealed an inhibitory effect of NaPB on G1-S-phase progression. Shortly after NaPB treatment, we found that PKC activity was activated rapidly but also decreased rapidly. Down-regulation of PKC-alpha and translocation of PKC-alpha from the cytosol to membrane were seen by Western blot. The decrease in PKC activity by NaPB corresponds to an enhanced response to radiation on CEN2 cells. Moreover, NaPB up-regulated EBV thymidine kinase activity to render EBV-associated Daudi cells susceptible to killing by GCV. Based on the observations of NaPB as a PKC modulator, the combination of NaPB, GCV, and radiation may provide a potential novel approach for treatment of EBV-associated NPC.
Chung
Y L
YL
Cancer Center, Veterans General Hospital-Taipei, Taiwan, Republic of China.
Lee
Y H
YH
Yen
S H
SH
Chi
K H
KH
D000998:Antiviral Agents / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000821:virology; D015774:Ganciclovir / Q000494:pharmacology; D018922:HL-60 Cells; D004854:Herpesvirus 4, Human / Q000201:enzymology; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010654:Phenylbutyrates / Q000494:pharmacology*; D011493:Protein Kinase C / Q000187:drug effects* / Q000378:metabolism; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D019098:Telomerase / Q000187:drug effects / Q000378:metabolism; D013937:Thymidine Kinase / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects / Q000821:virology
D000998:Antiviral Agents; D010654:Phenylbutyrates; D011838:Radiation-Sensitizing Agents; D013937:Thymidine Kinase; D011493:Protein Kinase C; D019098:Telomerase; D015774:Ganciclovir